Cargando…

Cost-effectiveness analysis of adebrelimab combined with chemotherapy for extensive-stage small cell lung cancer

Background: The findings of the CAPSTONE-1 trial showed that adebrelimab in combination with chemotherapy (etoposide-carboplatin) (ADCHM) is clinically beneficial as a first-line treatment for patients with extensive-stage small cell lung cancer (ES-SCLC), compared with placebo plus chemotherapy (PL...

Descripción completa

Detalles Bibliográficos
Autores principales: You, Maojin, Chen, Ruijia, Wu, Qingfeng, Zhu, Wei, He, Ying, Huang, Yufan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9643856/
https://www.ncbi.nlm.nih.gov/pubmed/36386191
http://dx.doi.org/10.3389/fphar.2022.1019826
_version_ 1784826612468940800
author You, Maojin
Chen, Ruijia
Wu, Qingfeng
Zhu, Wei
He, Ying
Huang, Yufan
author_facet You, Maojin
Chen, Ruijia
Wu, Qingfeng
Zhu, Wei
He, Ying
Huang, Yufan
author_sort You, Maojin
collection PubMed
description Background: The findings of the CAPSTONE-1 trial showed that adebrelimab in combination with chemotherapy (etoposide-carboplatin) (ADCHM) is clinically beneficial as a first-line treatment for patients with extensive-stage small cell lung cancer (ES-SCLC), compared with placebo plus chemotherapy (PLCHM, etoposide-carboplatin). However, owing to the higher cost of adebrelimab, it is unclear whether ADCHM is cost-effective compared with PLCHM. This study aimed to evaluate the cost-effectiveness of ADCHM as a first-line treatment for patients with ES-SCLC from the perspective of the Chinese healthcare system. Methods: A Markov model with three health states was developed to assess the cost-effectiveness of ADCHM as a first-line treatment option with ES-SCLC. Clinical data were obtained from the CAPSTONE-1 trial. Costs of the drug were calculated at national tender prices, and other costs and utility values were obtained from published literature. The outcomes included life years (LYs), quality-adjusted life years (QALYs), and incremental cost-effectiveness ratios (ICERs). One-way sensitivity analysis and probabilistic sensitivity analysis were used to validate the robustness of the model. Results: The ADCHM group achieved 1.21 QALYs (2.47 LYs) for $25,312, whereas the PLCHM group achieved 0.81 QALYs (1.59 LYs) for $14,846. The ICER for ADCHM versus PLCHM was $25914 per QALY gained. The variables with the greatest impact on the model results were the utility value of progressive disease, the utility value of progression-free survival, and the price of adebrelimab (100 mg). At a willingness-to-pay threshold of $37,653/QALY, ADCHM had an 89.1% probability of being cost-effective compared with PLCHM. Conclusion: ADCHM may be a cost-effective first-line treatment strategy for ES-SCLC from the perspective of the Chinese healthcare system.
format Online
Article
Text
id pubmed-9643856
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-96438562022-11-15 Cost-effectiveness analysis of adebrelimab combined with chemotherapy for extensive-stage small cell lung cancer You, Maojin Chen, Ruijia Wu, Qingfeng Zhu, Wei He, Ying Huang, Yufan Front Pharmacol Pharmacology Background: The findings of the CAPSTONE-1 trial showed that adebrelimab in combination with chemotherapy (etoposide-carboplatin) (ADCHM) is clinically beneficial as a first-line treatment for patients with extensive-stage small cell lung cancer (ES-SCLC), compared with placebo plus chemotherapy (PLCHM, etoposide-carboplatin). However, owing to the higher cost of adebrelimab, it is unclear whether ADCHM is cost-effective compared with PLCHM. This study aimed to evaluate the cost-effectiveness of ADCHM as a first-line treatment for patients with ES-SCLC from the perspective of the Chinese healthcare system. Methods: A Markov model with three health states was developed to assess the cost-effectiveness of ADCHM as a first-line treatment option with ES-SCLC. Clinical data were obtained from the CAPSTONE-1 trial. Costs of the drug were calculated at national tender prices, and other costs and utility values were obtained from published literature. The outcomes included life years (LYs), quality-adjusted life years (QALYs), and incremental cost-effectiveness ratios (ICERs). One-way sensitivity analysis and probabilistic sensitivity analysis were used to validate the robustness of the model. Results: The ADCHM group achieved 1.21 QALYs (2.47 LYs) for $25,312, whereas the PLCHM group achieved 0.81 QALYs (1.59 LYs) for $14,846. The ICER for ADCHM versus PLCHM was $25914 per QALY gained. The variables with the greatest impact on the model results were the utility value of progressive disease, the utility value of progression-free survival, and the price of adebrelimab (100 mg). At a willingness-to-pay threshold of $37,653/QALY, ADCHM had an 89.1% probability of being cost-effective compared with PLCHM. Conclusion: ADCHM may be a cost-effective first-line treatment strategy for ES-SCLC from the perspective of the Chinese healthcare system. Frontiers Media S.A. 2022-10-26 /pmc/articles/PMC9643856/ /pubmed/36386191 http://dx.doi.org/10.3389/fphar.2022.1019826 Text en Copyright © 2022 You, Chen, Wu, Zhu, He and Huang. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Pharmacology
You, Maojin
Chen, Ruijia
Wu, Qingfeng
Zhu, Wei
He, Ying
Huang, Yufan
Cost-effectiveness analysis of adebrelimab combined with chemotherapy for extensive-stage small cell lung cancer
title Cost-effectiveness analysis of adebrelimab combined with chemotherapy for extensive-stage small cell lung cancer
title_full Cost-effectiveness analysis of adebrelimab combined with chemotherapy for extensive-stage small cell lung cancer
title_fullStr Cost-effectiveness analysis of adebrelimab combined with chemotherapy for extensive-stage small cell lung cancer
title_full_unstemmed Cost-effectiveness analysis of adebrelimab combined with chemotherapy for extensive-stage small cell lung cancer
title_short Cost-effectiveness analysis of adebrelimab combined with chemotherapy for extensive-stage small cell lung cancer
title_sort cost-effectiveness analysis of adebrelimab combined with chemotherapy for extensive-stage small cell lung cancer
topic Pharmacology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9643856/
https://www.ncbi.nlm.nih.gov/pubmed/36386191
http://dx.doi.org/10.3389/fphar.2022.1019826
work_keys_str_mv AT youmaojin costeffectivenessanalysisofadebrelimabcombinedwithchemotherapyforextensivestagesmallcelllungcancer
AT chenruijia costeffectivenessanalysisofadebrelimabcombinedwithchemotherapyforextensivestagesmallcelllungcancer
AT wuqingfeng costeffectivenessanalysisofadebrelimabcombinedwithchemotherapyforextensivestagesmallcelllungcancer
AT zhuwei costeffectivenessanalysisofadebrelimabcombinedwithchemotherapyforextensivestagesmallcelllungcancer
AT heying costeffectivenessanalysisofadebrelimabcombinedwithchemotherapyforextensivestagesmallcelllungcancer
AT huangyufan costeffectivenessanalysisofadebrelimabcombinedwithchemotherapyforextensivestagesmallcelllungcancer